shire map
Select a

Shire Global

Better Health, Brighter Future

Genetic Diseases

Alpha_1 Antitrypsin DeficiencyMain ImageThere are an estimated 350 million people around the world living with a rare disease with 80% genetic in origin.1 This is an immense challenge that can seem insurmountable, but at Shire, we meet it head on by committing ourselves fully to the fight against these challenging conditions.

Rare genetic diseases can have symptoms that vary widely and progress very differently from person to person, which means that people affected by these diseases are frequently misdiagnosed.

We have a strong legacy in developing therapies for lysosomal storage disorders (LSDs), with a portfolio that includes commercial products, late-stage investigational therapies, and pipeline candidates, as well as a robust R&D program.

We empower global education and awareness, and partner with other medical and research organizations—continuously working to reduce the amount of time between the onset of symptoms and diagnosis, and accelerate the development of innovative new treatments.

Genetic diseases in our focus:

Fabry Disease

Fabry disease is a lysosomal storage disorder (LSD) that interferes with the body's ability to break down a specific fatty substance (globotriaosylceramide or Gb3). It affects an estimated 8,000 to 10,000 people worldwide, including both males and females.

Hunter Syndrome

Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a serious genetic disorder that primarily affects males. It interferes with the body's ability to break down and recycle specific mucopolysaccharides, also known as glycosaminoglycans or GAGs. Hunter syndrome is one of several related lysosomal storage diseases.

Type 1 Gaucher Disease

Type 1 Gaucher disease is a rare, inherited metabolic condition, and the most common of a family of rare diseases known as lysosomal storage disorders (LSDs). It affects approximately 1 in 100,000 people in the general population, and 1 in 855 people in the Ashkenazi Jewish community.2 Patients with type 1 Gaucher disease may experience varying symptoms and degrees of disease severity, making it difficult to diagnose.


  1. Global Genes Rare Disease Impact Report, Accessed January 23, 2018
  2. GuggenbuhlP, GrosboisB, ChalèsG. Gaucher disease. Joint Bone Spine. 2008;75(2):116-124.

S38373 03/18


Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE